← Back to Analyst Consensus 
SUPN Buy
SUPERNUS PHARMACEUTICALS, INC.
Current Price —
Implied Upside —
Analysts 11
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Oct 29, 2026 (3 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Jul 9, 2026 | Cantor Fitzgerald | maintain | Overweight → Overweight | — | 50% |
| Dec 19, 2025 | Stifel | maintain | Hold → Hold | $55 | 53% |
| Oct 29, 2025 | B of A Securities | initiate | — → Buy | $65 | 53% |
| Oct 23, 2025 | TD Cowen | maintain | Buy → Buy | $60 | 54% |
| Oct 9, 2025 | Piper Sandler | upgrade | Neutral → Overweight | $65 | 54% |
| Sep 30, 2025 | Cantor Fitzgerald | maintain | Overweight → Overweight | $63 | 50% |
| Aug 29, 2025 | Piper Sandler | maintain | Neutral → Neutral | $40 | 54% |
| Aug 6, 2025 | Cantor Fitzgerald | maintain | Overweight → Overweight | $46 | 50% |
| Feb 26, 2025 | Cantor Fitzgerald | reiterate | Neutral → Neutral | $36 | 50% |
| Feb 19, 2025 | Cantor Fitzgerald | downgrade | Overweight → Neutral | $36 | 50% |
| Sep 11, 2024 | Piper Sandler | downgrade | Overweight → Neutral | $36 | 54% |
| Feb 28, 2024 | Piper Sandler | maintain | Overweight → Overweight | $41 | 54% |
| Nov 9, 2023 | Piper Sandler | maintain | Overweight → Overweight | $43 | 54% |
| Oct 25, 2023 | Piper Sandler | maintain | Overweight → Overweight | $42 | 54% |
| May 10, 2023 | Piper Sandler | maintain | Overweight → Overweight | $46 | 54% |
| Jan 23, 2023 | Piper Sandler | maintain | — → Overweight | $47 | 54% |
| Aug 31, 2022 | Piper Sandler | maintain | — → Overweight | $38 | 54% |
| Apr 13, 2021 | Jefferies | upgrade | Hold → Buy | $40 | 52% |
| Jun 16, 2020 | Piper Sandler | upgrade | Neutral → Overweight | $31 | 54% |
| Apr 16, 2020 | Stifel | maintain | — → Hold | $24 | 53% |
| Nov 7, 2019 | Stifel | downgrade | Buy → Hold | $23 | 53% |
| Nov 6, 2019 | Jefferies | downgrade | Buy → Hold | $0 | 52% |
| Dec 17, 2018 | Mizuho | maintain | Buy → Buy | $63 | 52% |
| Nov 12, 2018 | B. Riley Securities | maintain | Buy → Buy | $65 | 54% |
| Sep 18, 2018 | Mizuho | initiate | — → Buy | $61 | 52% |
| Aug 9, 2018 | Jefferies | maintain | Buy → Buy | $58 | 52% |
| May 25, 2018 | Stifel | maintain | Buy → Buy | $60 | 53% |
| Feb 1, 2018 | Berenberg | initiate | — → Buy | $66 | 29% |
| Dec 4, 2017 | Janney Montgomery Scott | upgrade | Neutral → Buy | $0 | 55% |
| Nov 8, 2017 | B. Riley Securities | maintain | — → Buy | $50 | 54% |
| Nov 8, 2017 | Stifel | upgrade | Hold → Buy | $0 | 53% |
| Oct 19, 2017 | FBR Capital | initiate | — → Buy | $53 | — |
| Sep 19, 2017 | Stifel | downgrade | Buy → Hold | $0 | 53% |
| Jul 17, 2017 | Piper Sandler | downgrade | Overweight → Neutral | $0 | 54% |
| Jul 14, 2017 | Janney Montgomery Scott | initiate | — → Neutral | $47 | 55% |
| Jun 1, 2017 | Piper Sandler | upgrade | Neutral → Overweight | $44 | 54% |
| Dec 16, 2016 | Cantor Fitzgerald | initiate | — → Overweight | $32 | 50% |
| Aug 4, 2016 | Jefferies | maintain | — → Buy | $28 | 52% |
| Jul 18, 2016 | Northland Capital Markets | downgrade | Outperform → Market Perform | $0 | 50% |
| Jul 18, 2016 | Piper Sandler | downgrade | Overweight → Neutral | $0 | 54% |
| May 12, 2016 | Jefferies | maintain | — → Buy | $23 | 52% |
| Feb 8, 2016 | Jefferies | upgrade | Hold → Buy | $18 | 52% |
| Oct 28, 2015 | Northland Capital Markets | initiate | — → Outperform | $26 | 50% |
| Jun 18, 2015 | Stifel | maintain | — → Buy | $22 | 53% |
| Jun 18, 2015 | Piper Sandler | maintain | — → Overweight | $20 | 54% |
| Jun 18, 2015 | Jefferies | upgrade | Hold → Buy | $18 | 52% |
| Jun 12, 2015 | SunTrust Robinson Humphrey | initiate | — → Buy | $0 | — |
| Mar 12, 2015 | Jefferies | maintain | — → Hold | $11 | 52% |
| Apr 21, 2014 | Jefferies | initiate | — → Hold | $9 | 52% |
| Mar 14, 2014 | Stifel | maintain | — → Buy | $14 | 53% |
Price Target Trend
May 8, 2026 Oct 26, 2026
EPS Estimates
0y —
+1y —
+1q —
0q —
Cross-Platform Signals
No cross-platform signals in the last 90 days